We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to use a quasi-experimental study to evaluate your digital health product.
Using an ecological momentary assessment to evaluate your digital health product.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
This paper sets out principles for when the CMA will use field and online experiments and describes best practice for conducting them.
Information on granted EAMS scientific opinions, including the public assessment report and treatment protocols.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
A study which assesses the effect of randomised experimental designs on the analysis of genetically modified ingredients.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).